Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

p53 determines multidrug sensitivity of childhood neuroblastoma.

Cancer research - 1 Nov 2007

Xue Chengyuan, Haber Michelle, Flemming Claudia, Marshall Glenn M, Lock Richard B, MacKenzie Karen L, Gurova Katerina V, Norris Murray D, Gudkov Andrei V

Abstract excerpt

For pediatric cancers like neuroblastoma, the most common extracranial solid tumor of infancy, p53 mutations are rare at diagnosis, but may be acquired after chemotherapy, suggesting a potential role in drug resistance. Heavy metal-selected neuroblastoma cells were found to acquire an unusually broad multidrug resistance (MDR) phenotype but displayed no alterations in genes associated with "classic" MDR. These...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Drug Resistance, Multiple

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to G1 Phase

Share to Genes, p53

Share to Neuroblastoma

Share to Phenotype

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 17974978
DOI: 10.1158/0008-5472.CAN-06-4345

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

p53 determines multidrug sensitivity of childhood neuroblastoma.PMID 17974978Read ↗

Small-Molecule MDM2 Antagonists as a New Therapy Concept for NeuroblastomaSemantic proximity Read ↗

Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines.Semantic proximity Read ↗

p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma.Semantic proximity Read ↗

p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting RadioresistanceSemantic proximity Read ↗

Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction.Semantic proximity Read ↗

RLIP76 Inhibition: A Promising Developmental Therapy for Neuroblastoma.Semantic proximity Read ↗

MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.Semantic proximity Read ↗

Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours.Semantic proximity Read ↗

Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.Semantic proximity Read ↗

Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3.Semantic proximity Read ↗

A p53 Drug Response Signature Identifies Prognostic Genes in High-Risk NeuroblastomaSemantic proximity Read ↗

DNA‐damaging drug‐induced apoptosis sensitized by <i>N‐myc</i> in neuroblastoma cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.